Adalimumab Inhibits the Progression of Structural Joint Damage
Results from a randomized, placebo-controlled study investigating the ability of adalimumab to inhibit the progression of structural joint damage are now published (Keystone; Arthritis Rheum 50(5):1400, 2004). Patients with active RA in spite of methotrexate therapy were treated with either 40 mg every other week or 20 mg weekly adalimumab with concomitant methotrexate. Radiographic progression was statistically significantly less in both adalimumab treated groups when compared to the placebo group. See ACR highlights for detailed results.